Bing Liu
Research Subjects
Bing Liu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Donna Pascovici
Australian Proteomic Facility (APAF), Department of Molecular Science, Level 4, Room 432, 4 Wally's Walk, Macquarie University, NSW 2109, Sydney, Australia
1 shared publication - Matthew Keon
Neurodegenerative Disease section, Iggy Get Out (IGO), Boundary street, Darlinghurst NSW 2010. Sydney. Australia
1 shared publication - Matthew McKay
Australian Proteomic Facility (APAF), Department of Molecular Science, Level 4, Room 432, 4 Wally's Walk, Macquarie University, NSW 2109, Sydney, Australia
1 shared publication - Nitin K. Saksena
Victoria University
1 shared publication - Samuel Brennan
Neurodegenerative Disease section, Iggy Get Out (IGO), Boundary street, Darlinghurst NSW 2010. Sydney. Australia
1 shared publication - Thiri Zaw
Australian Proteomic Facility (APAF), Department of Molecular Science, Level 4, Room 432, 4 Wally's Walk, Macquarie University, NSW 2109, Sydney, Australia
1 shared publication
Latest Publications
- Open Access
- 29 March 2021
- Published by LIDSEN Publishing Inc in OBM Geriatrics
- Vol. 05 (01) , 1-21
Molecular Basis of Allogeneic Pluripotent Stem Cell Treatment of a Patient with Sporadic ALS
There are no curative strategies for ALS, and as a result the alternative therapies are gaining ground, in particular the stem cell-based therapies which hold a promising future. Here we describe an ALS patient, who by choice, received allogeneic human cord-blood derived multipotent stem cells (MSC) intravenously and intrathecally. This is the first snapshot of pre-and post-stem cell transplantation in an ALS patient through transcriptomic, epigenomic, and proteomic follow-up elucidating the effect of stem cells in ALS. Although new CSF proteins (FGA, B2M, FN1 and IGFBP3) were observed, but more work is needed to fully elucidate the effect based on larger cohorts in a clinical trial setting. These analyses may serve as a future guide to both scientists and clinicians alike in defining the utility of such cells in ALS treatment.
- 29 March 2021
- Published by LIDSEN Publishing Inc in OBM Geriatrics
- Vol. 05 (01) , 1-21
Open AccessMolecular Basis of Allogeneic Pluripotent Stem Cell Treatment of a Patient with Sporadic ALS
There are no curative strategies for ALS, and as a result the alternative therapies are gaining ground, in particular the stem cell-based therapies which hold a promising future. Here we describe an ALS patient, who by choice, received allogeneic human cord-blood derived multipotent stem cells (MSC) intravenously and intrathecally. This is the first snapshot of pre-and post-stem cell transplantation in an ALS patient through transcriptomic, epigenomic, and proteomic follow-up elucidating the effect of stem cells in ALS. Although new CSF proteins (FGA, B2M, FN1 and IGFBP3) were observed, but more work is needed to fully elucidate the effect based on larger cohorts in a clinical trial setting. These analyses may serve as a future guide to both scientists and clinicians alike in defining the utility of such cells in ALS treatment.